drugset / Trial / NCT01569256
Ovarian Hyperstimulation Syndrome and Cabergoline
Non-randomizedSingle-groupOpen-labelBasic science
Summary
Cabergoline prevents ovarian hyperstimulation syndrome in high risk patients by disrupting follicular fluid hormone microenvironmentally altering the follicular fluid levels of insulin like growth hormone -I (IGF-I), antimullerian hormone (AMH), inhibin B and hepatocyte growth factor (HGF) levels in women with PCOS and high risk of ovarian hyperstimulation syndrome (OHSS).
Timeline
- Start
- 2008-03
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cabergoline | Small molecule | 0.5 mg | — |